Pancreatic Cancer Research

ResearcherHuazhong University of Science and TechnologyActive in the last 2 years

Ming Xiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3048-3897; OpenAlex author ID A5073053328, A5121195941. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. YY1 Lactylation Elicits CARD9 Deficiency in Dendritic Cells Promoting Pancreatic Cancer Immune Escape. Last author DOI 10.7150/ijbs.131102↗
  2. REG3A promotes gemcitabine resistance in pancreatic cancer via the GPR54/ARRB2/ERK1/2 ligand-directed signaling pathway. Last author DOI 10.1016/j.bcp.2025.117322↗
  3. The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB … Last author DOI 10.1016/j.clim.2022.109217↗
  4. CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport. Last author DOI 10.1080/2162402x.2023.2204015↗
  5. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Last author DOI 10.1002/1878-0261.12443↗
  6. Microarray-based gene expression profiling reveals genes and pathways involved in the oncogenic function of REG3A on pancreatic cancer cells. Last author DOI 10.1016/j.gene.2015.12.039↗
  7. REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: Involvement of a REG3A-JAK2/STAT3 positive feedback loop. Last author DOI 10.1016/j.canlet.2015.03.014↗
  8. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer. Last author DOI 10.1007/s00109-014-1184-8↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Senlin Li · 5 shared papers, 2019–2026 · strength 0.97
  2. Cheng Tian · 4 shared papers, 2023–2026 · strength 0.89
  3. Lingyan Ding · 1 shared paper, 2026 · strength 0.30
  4. Mengzhu Zheng · 1 shared paper, 2026 · strength 0.30
  5. Jia Liu · 1 shared paper, 2025 · strength 0.24
  6. Qing Li · 1 shared paper, 2025 · strength 0.24
  7. Qing Li · 1 shared paper, 2023 · strength 0.18
  8. Ferdinando Nicoletti · 1 shared paper, 2023 · strength 0.18
  9. Qian Liu · 1 shared paper, 2023 · strength 0.17
  10. Qianqian Xu · 2 shared papers, 2016–2019 · strength 0.16
  11. Xiulan Liu · 2 shared papers, 2015–2016 · strength 0.13
  12. Zhongshi Zhou · 1 shared paper, 2019 · strength 0.09
  13. Rongrong Huang · 1 shared paper, 2019 · strength 0.09
  14. Li Xu · 1 shared paper, 2014 · strength 0.04
  15. Yong Kwon Han · 1 shared paper, 2014 · strength 0.04
  16. Xiulan Liu · 1 shared paper, 2014 · strength 0.04
  17. Jun Wang · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.